The study cohort recruited from Nordic university hospitals showed a high degree of risk factors; high age, AML at diagnosis, marrow fibrosis, complex karyotype, therapy-related disease and two thirds carrying multi-hit TP53 mutations. The gene discussed is TP53; the disease is acute myeloid leukemia.